Search results for "Prednisolone"

showing 10 items of 112 documents

Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.

2017

Background Inhibitory antibodies towards enzyme replacement therapy (ERT) are associated with disease progression and poor outcome in affected male patients with lysosomal disorders such as Fabry disease (FD). However, little is known about the impact of immunosuppressive therapy on ERT inhibition in these patients with FD. Methods In this retrospective study, we investigated the effect of long-term immunosuppression on ERT inhibition in male patients with FD (n = 26) receiving immunosuppressive therapy due to kidney (n = 24) or heart (n = 2) transplantation. Results No ERT-naive transplanted patient (n = 8) developed antibodies within follow-up (80 ±72 months) after ERT initiation. Seven (…

0301 basic medicineAdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentmedicine.medical_treatmentGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineMaintenance therapyInternal medicineInternal MedicineMedicineHumansEnzyme Replacement TherapyRetrospective StudiesKidneybusiness.industrynutritional and metabolic diseasesImmunosuppressionEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseAntibodies NeutralizingKidney TransplantationTacrolimusTransplantation030104 developmental biologymedicine.anatomical_structureImmunologyPrednisoloneFabry DiseaseHeart Transplantationbusiness030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugJournal of internal medicine
researchProduct

Hypertrophic pachymeningitis and cerebral venous thrombosis in myeloperoxidase-ANCA associated vasculitis

2019

Hypertrophic pachymeningitis (HP) is a circumscribed inflammatory process that thickens meninges with fibrous adhesions. Among the causes of HP, vasculitis and autoimmune disease should be considered; myeloperoxidase (MPO)-antinuclear cytoplasmatic antibodies (ANCA)-positivity can be the only

0301 basic medicinePathologymedicine.medical_specialtyImages In…PrednisoloneAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisANCA-Associated Vasculitis030105 genetics & heredityneurootologyvasculitisAntibodies Antineutrophil Cytoplasmic03 medical and health sciences0302 clinical medicinemedicineHumansskin and connective tissue diseasesPeroxidaseAutoimmune diseaseneuroimagingbiologybusiness.industryHeadacheMeningesmeningitisGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingVenous thrombosisTreatment Outcomemedicine.anatomical_structureMyeloperoxidasebiology.proteinFemaleSettore MED/26 - NeurologiaIntracranial ThrombosisAntibodyVasculitisbusinessheadache (including migraines)MeningitisBiomarkers030217 neurology & neurosurgeryBMJ Case Reports
researchProduct

Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease -- possible association with a st…

1999

Abstract Background/Aims: Antibodies to cytochrome P450 2D6, also knownas LKM1-autoantibodies, are characteristic for a subgroup of patients with autoimmune hepatitis, but can also occasionally be found in hepatitis C. We observed the occurrence of LKM1-autoantibodies 4 months after liver transplantation for Wilson's disease, in close association with a steroid-resistant rejection episode, in the absence of evidence for autoimmune hepatitis or hepatitis C. Methods: Sera from several time points prior to and following transplantation were tested for LKM-reactivity by immunofluorescence, ELISA and Western blotting. Antigen specificity was confirmed by Western blotting analysis on different cy…

AdultGraft RejectionMaleTime Factorsmedicine.medical_treatmentPrednisoloneDrug ResistanceEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisLiver transplantationKidneyHepatolenticular DegenerationAntibody SpecificityAzathioprinemedicineHumansAutoantibodiesHepatitisHepatologybiologybusiness.industryStomachHepatitis Cmedicine.diseaseVirologyLiver TransplantationTransplantationWilson's diseaseCytochrome P-450 CYP2D6Immunologybiology.proteinCyclosporineAntibodyViral hepatitisbusinessImmunosuppressive AgentsJournal of hepatology
researchProduct

Tacrolimus Monotherapy Without Steroids After Liver Transplantation – A Prospective Randomized Double-Blinded Placebo-Controlled Trial

2007

Early steroid withdrawal after liver transplantation (LT) is desirable in order to reduce steroid side effects. Between February 2000 and August 2004, 110 patients after LT were included in this prospective, randomized, double-blind, placebo-controlled trial. Randomization was performed before LT. In all patients, tacrolimus was used without induction therapy. All patients received methylprednisolon for 14 days, thereafter a double-blinded medication containing either placebo (n = 56) or methylprednisolon (n = 54) for 6 months, which was completely stopped thereafter. End points were patient and graft survival, acute and chronic rejection, and incidence of steroid side effects during the fi…

AdultGraft RejectionMalemedicine.medical_specialtyTime FactorsRandomizationmedicine.drug_classmedicine.medical_treatmentPlacebo-controlled studyLiver transplantationPlaceboMethylprednisoloneGastroenterologyTacrolimuslaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansImmunology and AllergyPharmacology (medical)Antibacterial agentTransplantationbusiness.industryMiddle AgedTacrolimusLiver TransplantationSurgeryCorticosteroidFemaleSafetybusinessImmunosuppressive AgentsFollow-Up StudiesAmerican Journal of Transplantation
researchProduct

High-Concentration Liquid Prednisolone Formula: Filling a Therapeutic Niche in Severe Acute Attacks of Urticaria and Angioedema.

2015

<b><i>Background/Aims:</i></b> According to current guidelines, the emergency kit for patients with severe urticaria and/or angioedema should include a corticosteroid with a prednisolone-equivalent of 50-100 mg. Since severe dysphagia may occur in anaphylaxis, liquid corticosteroids are advantageous. Presently, only liquid preparations with less than 100 mg prednisolone equivalent are available worldwide. <b><i>Methods:</i></b> We prepared a highly concentrated liquid prednisolone formula for oral administration (1 or 5 mg prednisolone per ml). We observed efficacy and safety of 100 mg or >250 mg liquid oral prednisolone in comparison to in…

AdultMaleAdolescentUrticariaPhysiologymedicine.drug_classmedicine.medical_treatmentPrednisoloneAnti-Inflammatory AgentsAdministration OralDermatologyDosage form030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineOral administrationmedicineHumansAngioedemaAgedPharmacologyHigh concentrationDosage FormsAngioedemabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemIntravenous therapyAnesthesiaPrednisoloneCorticosteroidFemalemedicine.symptombusinessAnaphylaxismedicine.drugSkin pharmacology and physiology
researchProduct

Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting in…

1995

Background. A single-institution, randomized open trial was prospectively performed to compare orally administered granisetron with or without intramuscularly administered methylprednisolone to metoclopramide plus methylprednisolone in the prevention of delayed nausea and vomiting induced by cisplatin-based chemotherapy. The effects of antiemetic treatments were evaluated from days 2 to 5 of the first cycle after cisplatin administration among patients who had never before received chemotherapy. Methods. All patients were treated with chemotherapeutic regimens containing cisplatin greater than or equal to 80 mg/m 2 and received antiemetic therapy with granisetron 3 mg intravenously for the …

AdultMaleCancer ResearchMetoclopramideNauseamedicine.drug_classMetoclopramideVomitingmedicine.medical_treatmentAdministration OralGranisetronMethylprednisoloneGranisetronNeoplasmsmedicineAntiemeticHumansProspective StudiesAgedChemotherapybusiness.industryNauseaMiddle AgedOncologyMethylprednisoloneAnesthesiaVomitingCorticosteroidAntiemeticsDrug Therapy CombinationFemalemedicine.symptomCisplatinbusinessmedicine.drugCancer
researchProduct

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

1999

No established medical therapy alters the progressive course of primary sclerosing cholangitis.To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis.Case series.University hospital in Mainz, Germany.15 patients with primary sclerosing cholangitis.Azathioprine (1 to 1.5 mg/kg of body weight per day), prednisolone (1 mg/kg per day initially, tapering to 5 to 10 mg per day) and UDCA (500 to 750 mg per day).Clinical and laboratory evaluation, liver biopsy, and endoscopic retrograde cholangiography (a30% change in stenosis was considered significant).After a median observation period of 41 months (ran…

AdultMaleCholagogues and Cholereticsmedicine.medical_specialtyPrednisolonemedicine.medical_treatmentCholangitis SclerosingPilot ProjectsAzathioprineAutoimmune hepatitisGastroenterologyInflammatory bowel diseasePrimary sclerosing cholangitisInternal medicineAzathioprineInternal MedicinemedicineHumansChemotherapybusiness.industryUrsodeoxycholic AcidGeneral Medicinemedicine.diseaseUlcerative colitisUrsodeoxycholic acidSurgeryRadiographyLiverPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugAnnals of Internal Medicine
researchProduct

Autoimmune hepatitis following Epstein-Barr virus infection

2008

We describe a case of a young man with autoimmune hepatitis (AIH) following Epstein–Barr virus (EBV) infection, in whom a long follow-up showed favourable outcome with complete clinical recovery and failure to relapse after cessation of immunosuppressive therapy. The study underlines the importance of the differential diagnosis between primary EBV associated hepatitis with features of autoimmunity, in which there is a direct pathogenetic role of the virus, and EBV related AIH, in which EBV could act as the trigger of the immune mediated damage with probable differences between the two conditions with regard to the prognosis and the responsiveness to immunosuppressive treatment. The favourab…

AdultMaleEpstein-Barr Virus InfectionsHepatitis Viral HumanAnti-Inflammatory AgentsAzathioprineDiseaseAutoimmune hepatitisSettore MED/08 - Anatomia Patologicamedicine.disease_causeMethylprednisoloneArticleVirusAutoimmunityDiagnosis Differentialimmune system diseaseshemic and lymphatic diseasesAzathioprinemedicineHumansEpstein–Barr virus infectionHepatitisbusiness.industryGeneral Medicinemedicine.diseasedigestive system diseasesHepatitis AutoimmuneLiverImmunologyDrug Therapy CombinationEBV autoimmune hepatitisDifferential diagnosisbusinessImmunosuppressive Agentsmedicine.drugCase Reports
researchProduct

Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy.

1996

Abstract Glucocorticoids are usually given for management of Graves' ophthalmopathy (GO), but they may cause side effects. By comparison, intravenous administration of immunoglobulins resulted in clinical improvement and decreased antibody titres in a large number of autoimmune diseases. Therefore, a randomized trial was done, in which 19 patients with active GO were treated with a 20-week course of oral prednisolone (P, starting dose 100 mg/day), and 21 received 1 g immunoglobulin/kg body weight for 2 consecutive days every 3 weeks. The immunoglobulin course was repeated six times. Before and at the end (20 weeks) of immunomodulating therapy, ophthalmological investigation and quantitative…

AdultMaleIntraocular pressureThyroid HormonesVisual acuityEye DiseasesGraves' diseasePrednisoloneImmunologyAdministration OralThyroglobulinlaw.inventionGraves' ophthalmopathyRandomized controlled triallawOral administrationmedicineImmunology and AllergyHumansProspective StudiesGlucocorticoidsAutoantibodiesbusiness.industryImmunoglobulins IntravenousReceptors ThyrotropinOriginal ArticlesMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAnti-thyroid autoantibodiesGraves DiseaseImmunologyPrednisoloneFemalemedicine.symptombusinessmedicine.drugClinical and experimental immunology
researchProduct

Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.

2001

Background Controlled trials have firmly established the need for immunosuppressive therapy in autoimmune hepatitis. However, reports about long-term management and prognosis of the disease are scarce. Patients and methods We reviewed the charts of 103 consecutive patients with a well-documented long-term course of autoimmune hepatitis who had been carefully managed over a mean observation period of 95 months (12-405 months). Results Under immunosuppressive therapy 94 patients (91.2%) reached complete remission after a mean treatment duration of 3 +/- 3 months. 28 of the 103 patients (27.2%) were eligible for a trial of treatment withdrawal after a mean treatment duration of 32.2 months (ra…

AdultMalePediatricsmedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentBiopsyPrednisoloneAzathioprineAutoimmune hepatitisLiver transplantationPharmacotherapyLiver Function TestsAzathioprineMedicineHumansChildCyclophosphamideAgedRetrospective StudiesAutoimmune diseaseHepatitismedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisLong-Term CareSurgeryHepatitis AutoimmuneLiverDrug Therapy CombinationFemalebusinessLiver function testsImmunosuppressive Agentsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct